Inventiva Reports H1 2026 Cash of €234M, Extends Runway to Q2 2027 After June Refinancing
IVA sits 53% above its 52-week low of $2.94.
Summary
Inventiva reported preliminary H1 2026 financials with €234 million in cash and deposits, reflecting the June capital optimization. Cash runway extends to Q2 2027, or Q1 2028 with contingent capital, but the company still faces a going-concern risk.
Key Events · Earnings and Guidance · IVA
-
H1 2026 Cash Position
Cash and cash equivalents of €166.1 million and short-term deposits of €67.8 million as of June 30, 2026, compared to €99.3 million and €131.6 million at year-end 2025.
-
Cash Burn and Runway
Net cash used in operations was €48.7 million in H1 2026. Existing resources fund operations into Q2 2027; with Tranche C debt (up to €20M) and full warrant exercise (up to €116M), runway extends to early Q1 2028.
-
June Refinancing Impact
Financing activities generated €50.9 million, driven by the €103 million equity offering and €75 million debt transaction, partially offset by €62 million EIB loan repayment and €50 million warrant repurchase.
-
Going Concern Risk
Current cash and equivalents are not sufficient to cover operating needs for the next 12 months; the company remains dependent on additional financing or contingent capital to continue as a going concern.
Analysis · IVA · Life Sciences
Inventiva disclosed preliminary first-half 2026 results, showing €166.1 million in cash and €67.8 million in short-term deposits as of June 30, 2026. The company burned €48.7 million in operations, offset by €63.9 million from investing and €50.9 million from financing — the latter reflecting the June 2026 capital overhaul that included a €103 million equity offering and €75 million debt transaction. Management now expects existing resources to fund operations into the second quarter of 2027, or into early 2028 if contingent capital (Tranche C debt and warrant exercises) materializes. The update confirms the company remains in a going-concern posture — current cash alone does not cover the next 12 months — but the runway extension from the June deals provides breathing room as the pivotal NATiV3 trial advances.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVA was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.94 to $7.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.